MCM
BIVV

Moore Capital Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Moore Capital Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,000
Closed -$1.5M – 275
2017
Q2 		$1.5M Buy
+25,000
New +$1.42M 0.05% 143

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Moore Capital Management's BIVV Position: Q3 2017 in Review

Moore Capital Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 25,000 shares — an estimated $1.5M sold.

Moore Capital Management first reported a position in BIVV in Q2 2017 and held it in 1 quarter. The position peaked at $1.5M in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Moore Capital Management reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Moore Capital Management sold 25,000 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $1.5M.
  • Moore Capital Management first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Moore Capital Management's Bioverativ Inc. Common Stock position peaked at $1.5M in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Moore Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.